Andrew Joseph

Andrew Joseph, STAT's European correspondent, sheds light on significant pharma pullbacks from the U.K., revealing why giants like Merck and GSK are shifting their investments elsewhere. He analyzes the pricing tensions and the impact of U.S. investment strategies on the U.K. life sciences landscape. The discussion also covers Roche's bold $3.5 billion acquisition of 89bio, reflecting a trend of steady biotech M&A activity and improving market sentiment, providing listeners with a clear perspective on industry dynamics.